NEW YORK (GenomeWeb News) – Pacific Biosciences has appointed Jonas Korlach to chief scientific officer, a position previously held by Eric Schadt, who will remain a key scientific advisor to the company.
Korlach was previously scientific fellow at PacBio, supporting commercial development of the PacBio RS system and performing research aimed at developing new applications for the system. He is a co-inventor of single molecule real-time sequencing technology along with Stephen Turner.
Prior to joining PacBio, Korlach was a postdoctoral researcher at Cornell University.
Quanterix has tapped Paul Chapman to be company president and CEO. Chapman recently was VP of EMD Millipore's BioPharm Process Solutions business, where he was responsible for marketing and R&D teams, and was previously VP of hospital solutions for Roche Near Patient Testing in Austria. Chapman also formerly was international business development manager at Roche Molecular Diagnostics, and he held a range of positions at Roche Diagnostics Canada.
Michael Rhodes has left his position at Life Technologies to join NanoString Technologies as director of collaboration and applications development, where he will focus on digital gene expression.
Rhodes held various positions at Life Tech, including most recently senior manager sequencing portfolio. He joined Applied Biosystems in 1999 in the genetic analysis division before the company merged with Invitrogen and became Life Tech.
In his new position, he will report to Joe Beechem, who recently joined NanoString from Life Tech, where he was most recently vice president, head of advanced sequencing and head of global sequencing chemistry, biochemistry, and biophysics.
NanoString also said this week that Greg Norden has been appointed to its board of directors, and to serve as chairman of the board's audit committee. Norden had a 21-year career at Wyeth, where he most recently was senior VP and CFO.
Greg Linder will retire from his positions at Abbott Laboratories as VP and controller, and his roles will be filled by Robert Funck, Abbott said in a Securities and Exchange Commission filing last week.
Funck has been with the company since 1987, and has most recently served as VP, chief ethics and compliance officer, and has served as treasurer and VP of internal audits.
Real Time Genomics has appointed Pamela Morley to be VP of worldwide commercial operations. Morley has 25 years of experience working in genomics and proteomics businesses. Morley recently was a VP at Fluidigm and spent two decades at Applied Biosystems, where she held the post of director of service for molecular biology, proteomics, and mass spectrometry products, among others.
Biodesix has appointed Domonic Spinella to be VP of clinical development and medical affairs.
Spinella most recently was executive director and head of translational and molecular medicine for Pfizer's Biotherapeutics division, and he led translational medicine for Pfizer Oncology and spent eight years at Chugai Pharmaceuticals USA, most recently as VP of exploratory research.
He also has served on national and international biomarker development bodies, including the Cancer Steering Committee of the NIH Biomarkers Consortium, the AACR/FDA/NCI/Cancer Biomarkers Collaborative, and the American Association for Cancer Research Scientific Review Committee for Molecular Diagnostics in Cancer Therapeutic Development.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.